Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Bestralingsboost verbetert biochemische ziektevrije overleving van prostaatcarcinoom
mei 2021 | Radiotherapie, Uro-oncologie